Subclinical atheromatosis localization and burden in a low-to-moderate cardiovascular risk population: the ILERVAS study
Por:
Bermudez-Lopez, M, Martinez-Alonso, M, Castro-Boque, E, Betriu, A, Cambray, S, Farras, C, Barbe, F, Pamplona, R, Lecube, A, Mauricio, D, Purroy, F, Valdivielso, JM, Fernandez, E
Publicada:
1 dic 2020
Resumen:
Introduction and objectives: There is a discrepancy between risk assessment based on cardiovascular risk factors (CVRF) and atheromatosis burden. The objective was to identify the prevalence of subclinical diseases with common risk factors, such as atheromatosis, occult kidney disease, prediabetes, and diabetes in a middle-aged population with low-to-moderate cardiovascular risk; to assess the vascular distribution, and severity of subclinical atheromatosis.
Methods: Randomized, interventional, longitudinal clinical trial. The intervention consisted of vascular ultrasound examination in the carotid and femoral arteries assessing 12 territories, combined with clinical, anthropometric, lifestyle, and biochemical parameters. Inclusion criteria consisted of women (aged 50-70 years) and men (aged 45-65 years) with at least 1 CVRF. Exclusion criteria consisted of a clinical history of diabetes, chronic kidney disease, or a prior CV event. Here, baseline characteristics of the ILERVAS cohort are shown.
Results: A total of 8330 middle-aged asymptomatic participants, 50.7% women, were enrolled. The presence of 1-2 CVRF was found in 74.8% and adherence to the Mediterranean diet was low in 52.8%. Several previously unknown chronic diseases were diagnosed, such as dyslipidemia (21.1%), hypertension (15.3%), kidney disease (15.4%), obesity (10.6%), and diabetes (2.3%). Subclinical atheromatosis was found in 71.4% of participants, localized in common femoral (54.5%), carotid bifurcation (41.1%) and internal carotid (22%). Intermediate atheromatosis (2-3 territories with atheroma plaque) was found in 32.6%, and generalized atheromatosis (>3 territories) in 19.7. Total plaque area was higher in men (0.97 cm(2) vs 0.58 cm(2), P < .001). Total plaque area was also higher in the femoral artery, and increased with the number of CVRF.
Conclusions: Subclinical atheromatosis was highly prevalent in a middle-aged population with low-to moderate cardiovascular risk, with 1 in 5 participants having generalized atheromatosis. (C) 2020 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved.
Filiaciones:
Bermudez-Lopez, M:
Red Invest Renal RedInRen ISCIII, Grp Invest Translac Vasc & Renal, IRBLleida, Lleida, Spain
Martinez-Alonso, M:
Univ Lleida, Dept Ciencies Med Bcis, Unitat Bioestadist, IRBLleida, Lleida, Spain
Castro-Boque, E:
Red Invest Renal RedInRen ISCIII, Grp Invest Translac Vasc & Renal, IRBLleida, Lleida, Spain
Betriu, A:
Red Invest Renal RedInRen ISCIII, Grp Invest Translac Vasc & Renal, IRBLleida, Lleida, Spain
Cambray, S:
Red Invest Renal RedInRen ISCIII, Grp Invest Translac Vasc & Renal, IRBLleida, Lleida, Spain
Farras, C:
Fundacio Inst Univ Recerca Atencio Primaria Salut, Ctr Atencio Primaria Cappont, Gerencia Terr Lleida, Barcelona, Spain
Fundacio Inst Univ Recerca Atencio Primaria Salut, Inst Catala Salut, Unitat Suport Recerca Lleida, Barcelona, Spain
Barbe, F:
Univ Lleida, Dept Med Resp, Hosp Univ Arnau Vilanova, Grp Recerca Translac Med Resp,IRBLleida, Lleida, Spain
Pamplona, R:
Univ Lleida, Dept Med Expt, IRBLleida, Lleida, Spain
Lecube, A:
Univ Lleida, Grp Recerca Obesitat & Metab ODIM, IRBLleida, Dept Endocrinol & Nutr,Hosp Univ Arnau de Vilanov, Lleida, Spain
Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain
Mauricio, D:
Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain
Hosp Santa Creu & Sant Pau, Dept Endocrinol & Nutr, Inst Recerca Biomed St Pau IIB St Pau, Barcelona, Spain
Purroy, F:
Univ Lleida, Grp Neurosci Clin, IRBLleida, Unitat Ictus,Hosp Univ Arnau de Vilanova, Lleida, Spain
Valdivielso, JM:
Red Invest Renal RedInRen ISCIII, Grp Invest Translac Vasc & Renal, IRBLleida, Lleida, Spain
Fernandez, E:
Red Invest Renal RedInRen ISCIII, Grp Invest Translac Vasc & Renal, IRBLleida, Lleida, Spain
|